文献速递肺血管病与心包/心肌炎心力衰竭与心肌病

NMDA型谷氨酸受体激活促进血管重塑与肺动脉高压

NMDA-Type Glutamate Receptor Activation Promotes Vascular Remodeling and Pulmonary Arterial Hypertension.
PubMed 文献 · Circulation · 2018-02-14

该研究探讨了谷氨酸-NMDAR轴在肺动脉高压(PAH)血管重塑中的作用。通过人肺组织分析、细胞实验及两种动物模型,发现PAH患者肺动脉中谷氨酸积累、NMDAR上调及GluN1磷酸化增加;平滑肌特异性NMDAR缺失或药物阻断可减轻血管重塑和改善心脏指标,提示血管NMDAR是PAH抗重塑治疗的潜在靶点。

要点

  • PAH患者肺动脉存在谷氨酸积累、NMDAR上调及GluN1磷酸化增加。
  • 平滑肌NMDAR缺失减轻慢性缺氧小鼠的血管重塑。
  • 药物阻断NMDAR改善 monocrotaline 大鼠的心脏和血管重塑。

核心结论

  • PAH患者肺动脉中谷氨酸-NMDAR轴失调,血管NMDAR是抗重塑治疗的潜在靶点。

研究设计与样本

  • 评估PAH患者与对照肺动脉中谷氨酸-NMDAR轴状态,采用质谱成像、Western blotting和免疫组化。
  • 培养肺血管细胞,用酶学试验测谷氨酸释放,Western blot分析NMDAR调控/磷酸化,BrdU掺入试验测NMDAR阻断对人肺动脉平滑肌细胞增殖的影响。
  • 使用平滑肌特异性NMDAR敲除小鼠暴露于慢性缺氧,及野百合碱大鼠肺动脉高压模型使用NMDAR阻断剂,评估NMDAR在血管重塑中的作用。

主要发现

  • PAH患者肺动脉中谷氨酸积累、NMDAR上调,GluN1亚基磷酸化增加反映NMDAR参与。
  • Kv通道抑制和A型选择性内皮素受体激活放大人类肺动脉平滑肌细胞钙依赖性谷氨酸释放。
  • A型选择性内皮素受体和血小板衍生生长因子受体激活导致NMDAR参与,提示谷氨酸-NMDAR轴与PAH相关通路交叉对话。
  • 血小板衍生生长因子-BB诱导的人肺动脉平滑肌细胞增殖涉及NMDAR激活和磷酸化GluN1亚基定位于细胞间接触。
  • 小鼠平滑肌NMDAR缺失减轻慢性缺氧触发的血管重塑;野百合碱大鼠模型中药物阻断NMDAR改善心脏和血管重塑,减少内皮功能障碍、细胞增殖和凋亡抵抗,同时破坏肺动脉中谷氨酸-NMDAR通路。

临床怎么用

  • 血管NMDAR可作为PAH抗重塑治疗的潜在靶点,药物阻断NMDAR在动物模型中显示有益效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Excessive proliferation and apoptosis resistance in pulmonary vascular cells underlie vascular remodeling in pulmonary arterial hypertension (PAH). Specific treatments for PAH exist, mostly targeting endothelial dysfunction, but high pulmonary arterial pressure still causes heart failure and death. Pulmonary vascular remodeling may be driven by metabolic reprogramming of vascular cells to increase glutaminolysis and glutamate production. The N-methyl-d-aspartate receptor (NMDAR), a major neuronal glutamate receptor, is also expressed on vascular cells, but its role in PAH is unknown. METHODS: We assessed the status of the glutamate-NMDAR axis in the pulmonary arteries of patients with PAH and controls through mass spectrometry imaging, Western blotting, and immunohistochemistry. We measured the glutamate release from cultured pulmonary vascular cells using enzymatic assays and analyzed NMDAR regulation/phosphorylation through Western blot experiments. The effect of NMDAR blockade on human pulmonary arterial smooth muscle cell proliferation was determined using a BrdU incorporation assay. We assessed the role of NMDARs in vascular remodeling associated to pulmonary hypertension, in both smooth muscle-specific NMDAR knockout mice exposed to chronic hypoxia and the monocrotaline rat model of pulmonary hypertension using NMDAR blockers. RESULTS: We report glutamate accumulation, upregulation of the NMDAR, and NMDAR engagement reflected by increases in GluN1-subunit phosphorylation in the pulmonary arteries of human patients with PAH. Kv channel inhibition and type A-selective endothelin receptor activation amplified calcium-dependent glutamate release from human pulmonary arterial smooth muscle cell, and type A-selective endothelin receptor and platelet-derived growth factor receptor activation led to NMDAR engagement, highlighting crosstalk between the glutamate-NMDAR axis and major PAH-associated pathways. The platelet-derived growth factor-BB-induced proliferation of human pulmonary arterial smooth muscle cells involved NMDAR activation and phosphorylated GluN1 subunit localization to cell-cell contacts, consistent with glutamatergic communication between proliferating human pulmonary arterial smooth muscle cells via NMDARs. Smooth-muscle NMDAR deficiency in mice attenuated the vascular remodeling triggered by chronic hypoxia, highlighting the role of vascular NMDARs in pulmonary hypertension. Pharmacological NMDAR blockade in the monocrotaline rat model of pulmonary hypertension had beneficial effects on cardiac and vascular remodeling, decreasing endothelial dysfunction, cell proliferation, and apoptosis resistance while disrupting the glutamate-NMDAR pathway in pulmonary arteries. CONCLUSIONS: These results reveal a dysregulation of the glutamate-NMDAR axis in the pulmonary arteries of patients with PAH and identify vascular NMDARs as targets for antiremodeling treatments in PAH.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Dumas SJ, Bru-Mercier G, Courboulin A, et al. NMDA-Type Glutamate Receptor Activation Promotes Vascular Remodeling and Pulmonary Arterial Hypertension. Circulation. 2018. PMID: 29444988. doi:10.1161/CIRCULATIONAHA.117.029930

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。